Status:

TERMINATED

Dose-ranging Study to Evaluate Efficacy of SLV339 in Pancreatic Exocrine Insufficiency Due to Chronic Pancreatitis

Lead Sponsor:

Solvay Pharmaceuticals

Conditions:

Pancreatic Exocrine Insufficiency Due to Chronic Pancreatitis

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

This study is to estimate the efficacy of a number of doses in patients with pancreatic insufficiency

Eligibility Criteria

Inclusion

  • Subject \> 18 years;
  • Pancreatic exocrine insufficiency confirmed and documented in medical history by either a pathophysiological direct or indirect pancreatic function test or clinical symptoms of steatorrhea stool fat that resolved or improved substantially upon pancreatic enzyme supplementation;
  • Patients on a stable daily dose of pancreatic enzymes for 3 months;
  • Subjects with CP with or without partial pancreatectomy due to CP, confirmed in medical history by either CT , ERCP, plain film with pancreatic calcifications, ultra-sonography (calcifications, duct dilatation), magnetic resonance pancreatography, endoscope ultrasound, other radiological diagnosis captured by tools such as Cambridge classification and /or histology;
  • CFA \< 80% at time of randomization

Exclusion

  • Evidence of major surgery (except gall bladder removal or appendectomy) or other relevant diseases as revealed by history, physical examination, and laboratory assessments which may interfere with the absorption, distribution, metabolism or elimination of the study drug or constitute a risk factor when taking the study medication;
  • Investigational drug intake within 90 days prior to the pre-assessment visit;
  • Ileus or acute abdomen;
  • Allergic disease such as hypersensitivity pneumonitis, aspergillus mediated asthma or allergic broncho-pulmonary aspergillosis;
  • Stenosis or regurgitation of the esophagus or stomach;
  • Known HIV infection, acute phase of CP

Key Trial Info

Start Date :

February 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 1 2009

Estimated Enrollment :

56 Patients enrolled

Trial Details

Trial ID

NCT00630279

Start Date

February 1 2008

End Date

March 1 2009

Last Update

August 6 2009

Active Locations (50)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 13 (50 locations)

1

Site 4206

Brno, Czechia

2

Site 4203

Hradec Králové, Czechia

3

Site 4202

Prague, Czechia

4

Site 4205

Prague, Czechia